Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat in CTEPH (CHEST-1)
NCT00855465Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2009
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in chronic thromboembolic pulmonary hypertension (CTEPH) comparing Riociguat with Placebo (2 arms). Primary endpoint: 6 Minutes Walking Distance at 16 weeks. Started Feb 2009; status: completed.
02
Drugs
riociguat
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT00855465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00855465.